Ropes & Gray represented FibroGen, Inc. in the transaction. FibroGen, Inc. (NASDAQ: FGEN) announced the sale of its China subsidiary, Fibrogen China, to AstraZeneca for approximately...
AstraZeneca’s $160 Million Acquisition of FibroGen China
FibroGen’s $150 Million Financing with Morgan Stanley Tactical Value
Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
FibroGen’s Royalty Monetization Financing with NovaQuest Capital Management
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...